Sitagliptin
Platelet Dysfunction
Hadassah Medical OrganizationSmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Platelet Dysfunction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Hadassah Medical Organization | Phase 2/3 | B |
N-Acetyl-L-Cysteine Hadassah Medical Organization | Phase 2/3 | B |
Deferiprone Hadassah Medical Organization | Phase 2/3 | B |
Same molecule, other indications
Sitagliptin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →